Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.37 |
| ▸ | FABP7 | O15540 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | POLM | Q9NP87 | 1/20 | 0.35 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.35 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.35 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725370 | 1.00 | TLR2 (0.39) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL727087 | 0.88 | FABP5 (0.40) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL725607 | 0.88 | FABP5 (0.40) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL727112 | 0.83 | FABP5 (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL25173099 | 0.82 | PTGIR (0.43) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL29855101 | 0.82 | PTGIR (0.43) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL25173097 | 0.82 | PTGIR (0.43) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL25173108 | 0.82 | FABP5 (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29855110 | 0.82 | FABP5 (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL2501976 | 0.78 | KMT2A (0.36) | TLR2KMT2AFABP5FABP7SOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10487129-B2 | Stabilized insulinotropic peptides and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| EP-2590997-B1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20170260248-A1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9695224-B2 | Stabilized insulinotropic peptides and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160159876-A1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9296805-B2 | Stabilized insulinotropic peptides and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130157942-A1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10487129-B2 | Stabilized insulinotropic peptides and methods of use | IAPP, VIP, GLP1R | TLR2 1448/4885KMT2A 4069/4885FABP5 1594/4885 |
| US-20130157942-A1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | IAPP, VIP, SI | TLR2 1445/4885KMT2A 4438/4885FABP5 2033/4885 |
| US-20160159876-A1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | IAPP, VIP, GLP1R | TLR2 1448/4885KMT2A 4069/4885FABP5 1594/4885 |
| US-20170260248-A1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | IAPP, VIP, GLP1R | TLR2 1448/4885KMT2A 4069/4885FABP5 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.